| Who we are | Contact details |
Headstart charity for head and neck cancers in Kent and Sussex


Headstart cancer charity

Latest news and info

Very latest research on Head & Neck Cancer 2017

Just published is the following article from

Wales on some new exciting research

which might have quite an impact on many other Cancers.

Click here to read the article


Headstart really can help!


Latest purchase by Headstart is this very "specialist hi-tec trolley".

This was requested by Mr Brian Bisase for the team at QVH to commence

a new treatment called electrochemotherapy. This treatment is used for treating

metastatic skin nodules to improve the quality of life in patients whose Cancer

is at a very advanced stage.


Click on the picture above to find out more about Mr Brian Bisase.


We ensure that Headstart makes a difference to the care

of the patients that are treated in the three

Kent & Sussex Hospitals that Headstart represents,

Medway Maritime, Maidstone and Queen Victoria Hospitals.

More newly purchased equipment below.


We purchased some vital medical equipment that will really make

a difference.

In Pauline Mortimer's words ..................

"Two new dopplers that Headstart has purchased will assist Head and

Neck Cancer patients. They will be used by Maxillofacial Surgeons

preparing patients ready for free flap surgery. 

The doppler identifies small blood vessels in

the legs to establish which part of the thigh or calf can be used to re-build

an area in the mouth, this is then marked with pen in readiness for surgery.

It will save patients from having to travel to QVH so many times in their

pre-op preparations.

The total cost was £1,149.60. A recent donation of £1000.00 from the

Penguins ensured the purchase of this equipment."


Is this the cure for cancer?


Genetically modified blood turned into 'living drug' in stunning new therapy that hunts down and destroys diseased cells and prevents them from returning - possibly FOREVER. 

Layla Richards became one of the first to be given the landmark treatment

She was given genetically engineering cells which killed off her leukemia. 

Studies reveal the treatment could last for at least 14 years in the body. It raises the prospect of a permanent cancer cure being widely available.

The ‘extraordinary’ results are ‘unprecedented in medicine’, the world’s biggest science conference heard

The ‘extraordinary’ results – seen in so-called ‘liquid’ cancers such as leukaemia rather than those that form solid tumours – are ‘unprecedented in medicine’, the world’s biggest science conference heard.

Researcher Chiara Bonini said: ‘This really is a revolution.’

The treatment is created from T-cells – white blood cells that normally fight off viruses and bacteria – which are removed from the patient and genetically tweaked to recognise and attack their cancer.

The genetically-modified cells are then grown in their millions in a lab before being infused back into the patient, where they hunt down and destroy the cancer cells. 

Scientists around the world are perfecting the technique, and a series of trials have shown it to have remarkable potential.

Some of the most exciting results come from the San Raffaele Scientific Institute in Milan, where doctors gave ten patients infusions of T-cells and watched how long they lasted in the body. 

One type of T-cell survived for 14 years, the conference of the American Association for the Advancement of Science heard.

Dr Bonini said these cells may last for life. If they were also genetically engineered to hunt out and destroy cancer, they would patrol the body year after year and stop it from ever returning.

She likened the therapy to a vaccine that gives protection for life against an infection, adding: ‘T-cells are a living drug and they have the potential to persist in our body for our whole lives. 

'Our findings have profound implications for the design of T-cell-based immunotherapies.’ 

Dr Bonini said patients were ‘very close’ to the first treatments becoming widely available.' 

Might this just be the way forward?


Following on from the above article is yet another recent piece

of research into H & N Cancer.


“This is really exciting!” Professor Christian Ottensmeier from

Southampton University tells us.

“We’re taking a drug being tested by a pharmaceutical company in

a group of patients and tryingit in a completely different group”.

Professor Ottensmeier is leading an exploratory clinical trial to

test a new drug, initially developed
as a leukaemia drug, in patients with cancers of the

Head and Neck.

Read the full article here.





Need help or further information?

Email headstartnews@gmail.com
Headstart support group


Copyright © 2010 Headstart

Website design by Footmark Media